BRUDY’s story is associated with research
on the healthy effects of omega-3
polyunsaturated fatty acids on human health
1995
Since the launch in 1995 of the first foods enriched with Omega-3 in Europe (eggs and milk), in 1998 began with the development chemistry of Omega-3 molecules for human medical applications. In 2001 we start laboratory enzymatic production.
2001
Launch of the first DHA 70% triglyceride;
a high concentration Omega-3 obtained
from fish.
2010
In 2010 the commercial division BRUDYLAB is created, which begins the commercialization of Food Supplements and Food for Special Medical Purposes for eye care, to promote fetal and neonatal neurodevelopment, liver and immune care, and starting the clinical research in all these areas.
2012
As of 2012, BRUDY expands its sales to Japan and Russia.
2015
In 2015 the patent is approved with a coverage for 90 countries (Asia, Europe, USA, Oceania) for ophthalmic use, in the central nervous system and in Oncology, and since then we began to publish the first clinical research results in the ocular area: dry eye, glaucoma, diabetic retinopathy, anterior uveitis, but also in sport, fertility, and we started the research into new areas such as hepatology, neuropediatrics (ADHD), obstetrics and neonatology.
2017
In 2017 the approval of the patent isratified by European courts, and begins the expansion to Mexico, Switzerland, Greece, Czech and Slovak Republics.
2019
In 2019 Italy and Brazil join.
2010-2022
In 2015 the patent is approved with a coverage for 90 countries (Asia, Europe, USA, Oceania) for ophthalmic use, in the central nervous system and in Oncology, and since then we began to publish the first clinical research results in the ocular area: dry eye, glaucoma, diabetic retinopathy, anterior uveitis, but also in sport, fertility, and we started the research into new areas such as hepatology, neuropediatrics (ADHD), obstetrics and neonatology.
27 years dedicated to research on the healthy effects of DHA, and at the service of human health.